Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Free Report) shares traded down 7.1% during trading on Monday . The stock traded as low as $1.67 and last traded at $1.71. 201,461 shares were traded during trading, a decline of 80% from the average session volume of 1,014,072 shares. The stock had previously closed at $1.84.
Hoth Therapeutics Stock Down 7.1 %
The firm has a market cap of $5.64 million, a price-to-earnings ratio of -0.27 and a beta of 0.47. The stock has a fifty day moving average price of $2.44 and a 200-day moving average price of $2.32.
Institutional Inflows and Outflows
Hoth Therapeutics Company Profile
Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.
- Five stocks we like better than Hoth Therapeutics
- How to Find Undervalued Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- The How And Why of Investing in Oil Stocks
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Basic Materials Stocks Investing
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.